Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.

JAMA network open - 3 Jul 2023

Matsubara Junichi, Mukai Kumi, Kondo Tomohiro, Yoshioka Masahiro, Kage Hidenori, Oda Katsutoshi, Kudo Ryo, Ikeda Sadakatsu, Ebi Hiromichi, Muro Kei, Hayashi Ryuji, Tokudome Nahomi, Yamamoto Nobuyuki, Muto Manabu

Abstract excerpt

IMPORTANCE: Precision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical utility of CGP before the standard of care (SOC) is still not resolved, and more evidence is needed. OBJECTIVE: To investigate the clinical utility of next-generation CGP (FoundationOne CDx [F1CDx]) in patients with previously untreated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Precision Medicine

Share to Recurrence

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 37459099
DOI: 10.1001/jamanetworkopen.2023.23336
PMCID: PMC10352863

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.PMID 37459099Read ↗

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read ↗

Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancerSemantic proximity Read ↗

A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.Semantic proximity Read ↗

Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.Semantic proximity Read ↗

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsSemantic proximity Read ↗

Clinical and diagnostic utility of genomic profiling for digestive cancers: real-world evidence from JapanSemantic proximity Read ↗

Feasibility of Point-of-Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary.Semantic proximity Read ↗

Comprehensive Genomic Profiling in Metastatic Solid Tumors: High Actionability But Low Implementation in Real-World PracticeSemantic proximity Read ↗

Prognostic impact of cancer genomic profile testing for advanced or metastatic solid tumors in clinical practice.Semantic proximity Read ↗

Prognostic impact of genomically matched therapy for solid cancers using real-world data from a provincial hospital in JapanSemantic proximity Read ↗

Next-Generation Sequencing-Based Evaluation of the Actionable Mutational Landscape in Solid Tumors: the “MOZART” Prospective Observational StudySemantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.